Table 4.
Time to switch by reasons for switching
| All switchersa (N = 352) | Switch to alternative TNFi (N = 246) | Switch to non-TNFi (N = 106) | p valueb | p valuec | ||
|---|---|---|---|---|---|---|
| Time (months) to first switch | Median [IQR] | 6.0 [4.0, 9.1] | 6.0 [3.9, 9.0] | 6.5 [4.0, 10.0] | 0.486 | |
| Switch with ≥ 1 reason given: | n (%) | 263 (74.7) | 179 (72.8) | 84 (79.2) | 0.3887 | |
| Efficacy | n (%) | 159 (60.5) | 104 (58.1) | 55 (65.5) | ||
| Time (months) to switch | Median [IQR] | 7.0 [4.0, 10.0] | 6.0 [4.0, 10.0] | 7.0 [4.0, 10.0] | 0.476 | |
| Safety | n (%) | 40 (15.2) | 26 (14.5) | 14 (16.7) | ||
| Time (months) to switch | Median [IQR] | 6.0 [4.0, 9.0] | 6.0 [4.0, 9.0] | 6.0 [4.0, 11.0] | 0.987 | |
| Other than efficacy or safetyd | n (%) | 62 (23.6) | 48 (26.8) | 14 (16.7) | ||
| Time (months) to switch | Median [IQR] | 6.0 [3.0, 9.0] | 6.0 [3.5, 9.0] | 4.5 [3.0, 6.0] | 0.120 |
IQR interquartile range, TNFi tumor necrosis factor inhibitor
aPatients may have switched more than once during the 12-month observation period; only the first switch was reported
bp value for comparing time to first switch (months) to alternative TNFi vs. switch to non-TNFi
cp value for comparing the proportion of patients who switch to alternative TNFi vs. switch to non-TNFi
dTwo patients switched because of ‘efficacy and safety’; data not included